Overview and management of dermatologic events associated with targeted therapies for medullary thyroid cancer Journal Article


Authors: Lacouture, M. E.; Ciccolini, K.; Kloos, R. T.; Agulnik, M.
Article Title: Overview and management of dermatologic events associated with targeted therapies for medullary thyroid cancer
Abstract: Background: Treatment options for patients with advanced or metastatic medullary thyroid cancer (MTC) have, in recent years, expanded with the approval of two tyrosine kinase inhibitors (TKIs): vandetanib and cabozantinib. Other agents, including TKIs, are under clinical investigation for MTC. Although patients treated with TKIs are at risk of developing dermatologic adverse events (AE), these untoward eventsmay be mitigated throughAE-driven algorithms. Summary: AE-driven algorithms combine effective nonpharmaceutical and pharmaceutical treatment modalities implemented by a multidisciplinary effort that incorporates nursing interventions, patient education, and referrals to pain-management specialists, podiatrists, and dermatologists, as appropriate.EffectiveAEprevention and management reduce the need for dose interruptions andmodifications, allowing patients the opportunity to derive themaximal benefit from TKI therapy, while maintaining quality of life. Conclusions: Optimal use of targeted therapies in the treatment of MTC depends on careful patient selection, interdisciplinary communication, and patient education and encouragement to enhance compliance and safety, optimize consistent dosing, and maximize the use of effective therapies. © Mary Ann Liebert, Inc.
Journal Title: Thyroid
Volume: 24
Issue: 9
ISSN: 1050-7256
Publisher: Mary Ann Liebert, Inc  
Date Published: 2014-09-01
Start Page: 1329
End Page: 1340
Language: English
DOI: 10.1089/thy.2013.0700
PROVIDER: scopus
PMCID: PMC4148058
PUBMED: 24902006
DOI/URL:
Notes: Export Date: 1 October 2014 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Mario E Lacouture
    457 Lacouture